IPA Expert Consensus Conference “Vascular Burden of the Brain: New Therapeutic Directions” TRIL DESIGNS: SLOW PROGRESSION
White-Matter Changes on MRI as Surrogate Marker
Philip Scheltens a1, Frederik Barkhof a2andFranz Fazekas a3 a1 Department of Neurology and the Alzheimer Centre, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands a2 Department of Radiology and the Image Analysis Centre, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands a3 Department of Neurology, Karl-Franzens University, Graz, Austria
This article reviews the use of white-matter changes as identified on MRI as a surrogate marker in clinical trials on vascular dementia. As of yet, insufficient evidence is present to implement rating or volumetric assessment of the burden of white-matter changes as surrogate marker in such trials, in view of the limited sensitivity to change of current methods and the high measurement error.
